UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2022

Foghorn Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-39634**	**47-5271393**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

500 Technology Square, Ste 700
Cambridge, MA **02139**
(Address of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code): (617) 586-3100

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.0001 par value per share	**FHTX**	**The Nasdaq Global Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 8, 2022, Foghorn Therapeutics Inc. (the "Company") issued a press release announcing certain of the Company's financial results for the quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated November 2022, which the Company intends to use in meetings with or presentations to investors.

The information in this Item 7.01 (including Exhibit 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued on November 8, 2022
99.2	Investor Presentation dated November 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FOGHORN THERAPEUTICS INC.

By: /s/ Allan Reine
Allan Reine, M.D.
Chief Financial Officer

Date: November 8, 2022

Exhibit 99.1

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

- FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023
- FHD-609 Phase 1 pharmacodynamic data shows degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies; initial Phase 1 dose escalation efficacy and safety data expected in 2023
- Continue to advance preclinical pipeline with novel targets including BRM, ARID1B and CBP
- Cash, cash equivalents and marketable securities of $373.5 million, as of September 30, 2022, provides significant cash runway into 2025

CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) -- November 8, 2022 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today
provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended September 30, 2022. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people with a wide spectrum of diseases.

"This quarter, we advanced our deep pipeline of over fifteen programs including our newly disclosed selective CBP protein degrader program, BRM, and ARID1B, all having significant unmet medical need. Early clinical data for our BRD9 degrader program, FHD-609, reinforced our broad and unique capabilities in protein degradation development, further establishing Foghorn as a leader in the field," said Foghorn CEO Adrian Gottschalk. "As we look ahead, our strong balance sheet supports us through important clinical milestones including the Phase 1 dose escalation study evaluating FHD-286 in metastatic uveal melanoma, with initial data expected in the first half of 2023, and our FHD-609 program in synovial sarcoma, where we remain on track to report data in 2023."

Key Recent Updates

- **FHD-286 mUM Update**. The dose escalation Phase 1 study of FHD-286, an inhibitor of BRG1/BRM, in metastatic uveal melanoma (mUM) continues to enroll patients per protocol. Initial phase 1 clinical data is expected in the first half of 2023.
- **FHD-286 AML/MDS Update**. In August 2022, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on the Phase 1 dose escalation study in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The full clinical hold in the AML/MDS study is due to the observation, in the data submitted in response to a partial hold, of additional suspected cases of fatal differentiation syndrome believed to be associated with FHD-286. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that has been seen with, and is believed to be on-target for the proposed mechanism of action for, FHD-286. The FDA has additional questions and requires further analyses

before the clinical hold may be lifted. The Company continues to work to resolve the clinical hold with the FDA.

- **FHD-609 Update**. Patient enrollment is continuing in the Phase 1 dose escalation clinical study of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma and SMARCB1-loss tumors with initial efficacy and safety data expected in 2023.

  Initial clinical data from two patients with metastatic synovial sarcoma in the ongoing Phase 1 dose escalation study, treated with the same low dose of FHD-609, showed degradation of BRD9 in on-treatment metastatic tumor biopsies. This data was presented at Hanson Wade's 5th Annual Targeted Protein Degradation Summit on October 26. Additional preclinical data presented at the same conference demonstrated that FHD-609 is highly selective, with no off-target IMid neosubstrate impact, potentially avoiding the adverse effects associated with unwanted off-target degradation.

- **Selective CBP Program Announced**. In October 2022, Foghorn disclosed a selective CBP degrader targeting EP300 mutant cancers. The Selective CBP program is aimed at degrading the CREB binding protein and has therapeutic potential in subsets of several cancers including bladder, colorectal, breast, gastric and lung. Using selective CBP degraders, the program aims to exploit the synthetic lethal relationship it shares with its paralog EP300 to identify and treat those patients with EP300 mutated cancers. If successful, the Selective CBP program has the potential to address over 100,000 patients in many cancer types.

- **Pipeline Advancement**. Foghorn continues to expand its protein degradation capabilities and platform. Over half of the Company's programs leverage the protein degradation modality. Ongoing investments include undisclosed heterobifunctional PROTAC and non-cereblon molecular glue programs, in addition to the progression of the more advanced selective protein degrader programs of BRM, CBP, and ARID1B, all with significant unmet medical need.

- **Board of Directors Updates**. Foghorn announced the election of B. Lynne Parshall, Esq., and Thomas J. Lynch Jr., M.D., to its Board of Directors. Cigall Kadoch, Ph.D., a co-founder of the Company, accepted her appointment as an Investigator for the Howard Hughes Medical Institute (HHMI) and, in accordance with HHMI's rules, resigned from Foghorn's Board of Directors. Dr. Kadoch remains with the Company as a Scientific Advisor to the Board and will continue to participate on Foghorn's Scientific Advisory Board.

- **Merck Collaboration Update**. In July 2022, a research milestone was achieved under the Merck collaboration triggering a $5 million milestone payment to Foghorn, which was reflected in the financial statements for the quarter ended September 30, 2022.

Third Quarter 2022 Financial Highlights

- **Strong Balance Sheet and Cash Runway**. As of September 30, 2022, the Company had $373.5 million in cash, cash equivalents and marketable securities.

- **Collaboration Revenues**. Collaboration revenues were $6.6 million for the third quarter of 2022 compared to $0.1 million for the third quarter of 2021. The increase was primarily driven by revenue recognized under the Lilly collaboration agreement, which was executed in December 2021.

- **Research and Development Expenses**. Research and development expenses were $26.9 million for the third quarter of 2022 compared to $20.5 million for the third quarter of 2021. This increase was primarily due to costs associated with continued investment in R&D personnel and the Phase 1 studies for both FHD-286 and FHD-609, which were initiated in 2021.

- **General and Administrative Expenses**. General and administrative expenses were $8.0 million for the third quarter of 2022, compared to $5.8 million for the third quarter of 2021. This increase was primarily due to an increase in investments to support the growing business.

- **Net Loss**. Net loss was $25.8 million for the third quarter of 2022 compared to a net loss of $26.1 million for the third quarter of 2021.

About FHD-286
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors. To learn more about these studies please visit ClinicalTrials.gov. (Link here for metastatic uveal melanoma and here for AML and MDS).

About AML
Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

About Uveal Melanoma
Uveal (intraocular) melanoma (UM) is a rare eye cancer that forms from cells that make melanin in the iris, ciliary body and choroid. It is the most common eye cancer in adults. It is diagnosed in about 2,000 adults every year in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years. However, it can occur in all races and at any age. UM metastasizes in approximately 50% of cases, leading to very poor prognosis.

About FHD-609
FHD-609 is a potent, selective, intravenously administered protein degrader of BRD9, a component of the ncBAF complex. Preclinical studies have demonstrated tumor growth inhibition in synovial sarcoma, a cancer genetically dependent on BRD9. To learn more about the first-in-human clinical trial of FHD-609 in synovial sarcoma, please visit ClinicalTrials.gov.

About Synovial Sarcoma
Synovial sarcoma is a rare, often aggressive soft tissue sarcoma that originates from different types of soft tissue, including muscle or ligaments. Synovial sarcoma can occur at any age but is most common among adolescents and young adults. It represents around 5-10% of all soft tissue sarcomas, with ~800 new cases each year in the United States. Surgery remains the most effective treatment for synovial sarcoma, and there are limited therapeutic treatment options.

About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains "forward-looking statements" regarding the Company's clinical programs for FHD-286 and FHD-609, including its efforts to resolve the full clinical hold relating to FHD-286 in AML and MDS, the anticipated timing of release of clinical data, its collaborations with Lilly and Merck and its research pipeline, including its degrader efforts. Forward-looking statements include statements regarding the Company's clinical trials, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Condensed Consolidated Balance Sheets
(In thousands)

	Sept. 30, 2022	Dec. 31, 2021
Cash, cash equivalents and marketable securities	$ 373,498	$ 154,289
Collaboration receivable	—	300,000
All other assets	60,434	65,485
Total assets	**$ 433,932**	**$ 519,774**
Deferred revenue, total	$ 341,003	$ 351,047
All other liabilities	68,606	71,856
Total liabilities	**409,609**	**422,903**
Total stockholders' equity	**24,323**	**96,871**
Total liabilities and stockholders' equity	**$ 433,932**	**$ 519,774**

Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)

	Three Months Ended September 30,	
	2022	2021
Collaboration revenue	$ 6,634	$ 41
Operating expenses:		
Research and development	26,928	20,494
General and administrative	7,965	5,808
Total operating expenses	**34,893**	**26,302**
Loss from operations	**(28,259)**	**(26,261)**
Total other income, net	**2,490**	**181**
Net loss	**$ (25,769)**	**$ (26,080)**
Net loss per share attributable to common stockholders—basic and diluted	$ (0.62)	$ (0.71)
Weighted average common shares outstanding—basic and diluted	**41,672,621**	**36,971,767**

Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media)
michael@scientpr.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

Exhibit 99.2

FOGHORN® THERAPEUTICS

CORPORATE OVERVIEW

Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond

November 2022

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: the potential outcomes from the Collaboration Agreement with Lilly; the initiation, timing, progress and results of our research and development programs and preclinical and clinical trials, including the potential resolution of the full clinical hold and anticipated timing of release of clinical data; our ability to advance product candidates that we may develop and to successfully complete preclinical and clinical studies; our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control Platform; the impact of the COVID-19 pandemic on our and our collaborators’ business operations, including our research and development programs and preclinical studies; developments related to our competitors and our industry; our ability to expand the target populations of our programs and the availability of patients for clinical testing; our ability to obtain regulatory approval for FHD-286, FHD-609 and any future product candidates from the FDA and other regulatory authorities; our ability to identify and enter into future license agreements and collaborations; our ability to continue to rely on our CDMOs and CROs for our manufacturing and research needs; regulatory developments in the United States and foreign countries; our ability to attract and retain key scientific and management personnel; the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-286 and FHD-609, our future products and our Gene Traffic Control Platform; and our use of proceeds from capital-raising transactions, estimates of our expenses, capital requirements and needs for additional financing. Any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The Company’s business is subject to substantial risks and uncertainties.

FIRST-IN-CLASS PRECISION MEDICINES TARGETING CANCER AND OTHER DISEASES

LARGE MARKET POTENTIAL

Chromatin biology implicated in up to **50% of cancer**, potentially impacting **~2.5 million patients**

Potential applications in virology, autoimmune diseases and neurology

WELL-FUNDED

$373.5 million in cash and equivalents

(as of 9/30/2022)

UPCOMING MILESTONES

FHD-286: Initial clinical data for mUM expected H1'23

FHD-286: AML/MDS study on full clinical hold, initial clinical data TBD

FHD-609: Initial clinical data expected in 2023

SIGNIFICANT GLOBAL PARTNERSHIPS

Strategic collaboration with Loxo Oncology at Lilly; $380 million upfront; 50/50 U.S. economic split on two lead programs

Merck collaboration to drug single specified transcription factor target; $15 million upfront and up to $410 million in milestones

EXPERIENCED LEADERSHIP TEAM

Expertise across drug discovery, clinical development and commercialization

UNIQUE INSIGHTS INTO CHROMATIN BIOLOGY

Untapped Area for Novel Targets and Therapeutics

CHROMATIN REGULATORY SYSTEM CRITICAL FOR GENE EXPRESSION



Chromatin – compacted form of DNA inside the nucleus of the cell

NOVEL TARGETS GUIDED BY GENETIC DEPENDENCIES

Chromatin Remodeling Complex Mutations / Overexpression



Transcription Factor Mutations / Overexpression

Mutations That Impinge on the Chromatin Regulatory System

TAILORED DRUGGING APPROACHES

Targeted Protein Degradation: Molecular glue and bi-functional protein degraders

Enzymatic Inhibitors: Highly selective and allosteric small molecule inhibitors

Transcription Factor Disruptors: Disrupt interactions between chromatin remodeling complexes and transcription factors

FOGHORN'S GENE TRAFFIC CONTROL® PLATFORM

Integrated, Scalable, Efficient – Repeatable Paradigm



Unique Targets

Deep Mechanistic Understanding of the Chromatin Regulatory System

What to Drug: Identify disease dependencies



Specialized Approach

Biochemistry, Biophysics and Assays of Large Complexes and Proteins

How to Drug: Biology first - small molecule modality agnostic

Selective Therapeutics

Small Molecule and Degrader Platform

Where to Drug: Engineer selectivity via unique assays and protein capabilities

BROAD PIPELINE ACROSS A RANGE OF TARGETS AND MODALITIES

Precision Oncology / Breadth and Depth / Over 15 Programs

* Per year incidence U.S., EU5, Japan

FOGHORN THERAPEUTICS

FHD-286

In Phase 1 Dose Escalation for AML / MDS & Uveal Melanoma

FHD-286 is a Potent, Selective, Allosteric, Small Molecule Inhibitor of the BRG1 and BRM subunits of the BAF complex

FHD-286 TARGETS ABNORMAL DEPENDENCIES ON BAF IN CANCER

Target / Approach	• BRG1 / BRM ATPase • Small molecule, allosteric, oral enzymatic inhibitor
Indications	• Acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) • Uveal melanoma • Indication expansion work ongoing in multiple solid tumors
Mutation / Aberration	• **AML**: Elevated BRG1-BAF / TF activity in AML blast cells • **Uveal melanoma**: GNAQ / GNA11 mutated UM is driven by dependency on BAF / TF activity
Program Status / Milestones	• Phase 1 study enrolling in mUM, initial clinical data expected H1'23 • AML/MDS study on full clinical hold, initial clinical data TBD
New Patients Impacted / Year*	• **AML**: Over 20,000 relapsed and / or refractory patients • **MDS**: Over 7,000 high-risk MDS patients • **Uveal melanoma**: Over 5,000 patients

* U.S., EU5, Japan

BAF CHROMATIN REMODELING COMPLEX



- BRM / BRG1 is the engine (ATPase) of the BAF chromatin remodeling complex
- BRG1 & BRM are highly similar proteins

FHD-286 CLINICAL DEVELOPMENT PLAN

Two Parallel Phase 1 Studies

PHASE 1 DOSE ESCALATION STUDIES

- Relapsed / Refractory AML & MDS
- Metastatic Uveal Melanoma

Phase 1 Study Designs

- Single patient accelerated titration (n=1)
- Convert to 3+3 once relevant PK / PD, safety or clinical activity observed
- Retrospective biomarker analysis to further evaluate safety and efficacy
- Assess safety, PK, biomarkers and efficacy

PHASE 1 EXPANSION STUDIES

- Expansion cohorts in AML, UM and potentially other indications

POTENTIAL DEFINITIVE EFFICACY TRIALS & INDICATION EXPANSION

- Potential for entry into definitive efficacy trials in AML
- Potential for entry into definitive efficacy trials in metastatic UM
- Potential for indication expansion beyond AML and UM

AML: DEPENDENCY ON BRG1 / LINEAGE TF INTERACTIONS



FHD-286 SHOWS EFFECT ACROSS A BROAD RANGE OF MUTATIONS IN AML PATIENT-DERIVED SAMPLES



PRECLINICAL FHD-286 DATA SHOWS EFFICACY ACROSS AML PATIENT-DERIVED SAMPLES

Notable Patient ID	Deep Response	Pathology Review	Disease Status
1690AML1	Y	AML	Secondary
1695AML1	Y	AML/MDS	Secondary
1696AML1	Y	AML	Secondary
1701AML1	Y	AML	Secondary
1893AML1	Y	AML	R/R
1899AML1	Y	AML	R/R
1990pAML1	Y	AML	R/R
1991pAML1	Y	AML	de novo
2041AML1	Y	N/A	de novo
2043pAML1	Y	AML	R/R
2059AML1	Y	AML	R/R
1682AML1	~	N/A	N/A
1689AML1	~	AML/MDS	de novo
1684AML1	N	CML	R/R
1924AML1	N	AML/MDS	R/R

Y = Deep reduction in blast cells ~ = Partial reduction N = No response



- Response observed in a majority of primary AML samples, irrespective of prior treatment or disease stage
- Additional data set from patient-derived samples demonstrate mutation-agnostic responses

DOSE-DEPENDENT TUMOR GROWTH INHIBITION OBSERVED WITH FHD-286 TREATMENT IN AML CDX MODELS

MV4-11 CDX Model
(FLT3 ITD, MLL-AF4)





OCI-AML2 CDX MODEL
(MII-AF6, DNMT3A MUT.)





Vehicle — FHD-286, 0.5 mg/kg, PO, QD — FHD-286, 1.5 mg/kg, PO, QD

TUMOR GROWTH INHIBITION WITH FHD-286 TREATMENT OBSERVED BY BIOLUMINESCENCE

Imaging in a Disseminated AML Model

VEHICLE





FHD-286
1.5 MG / KG, BID
(5ON / 8OFF) X3

FHD-286
1.5 MG / KG
QDX28





SORAFENIB
15 MG / KG,
QDX14

FHD-286 SURVIVAL ADVANTAGE IN DISSEMINATED AML MODEL



THERAPEUTIC RATIONALE FOR UVEAL MELANOMA

Dependency on Two Lineage Transcription Factors MITF / SOX10

BIOLOGY

OVER 85% OF UVEAL MELANOMA CANCERS HAVE GNAQ OR GNA11 MUTATIONS



VALIDATION OF DEPENDENCY AND APPROACH





FHD-286 WAS ASSOCIATED WITH DOSE-DEPENDENT TUMOR REGRESSION IN UVEAL MELANOMA CDX MODELS AT TOLERATED DOSES

MP-46 UVEAL MELANOMA CDX MODEL

Dose-dependent tumor growth inhibition

Well-tolerated



92-1 UVEAL MELANOMA CDX MODEL

Dose-dependent tumor growth inhibition

Tumor regression at 1.5 mg / kg, PO, QD

Well-tolerated

Vehicle — FHD-286, 0.5 mg/kg, PO, QD — FHD-286, 1.5 mg/kg, PO, QD

FHD-609

In Phase 1 Dose Escalation for Synovial Sarcoma and SMARCB1-Loss Tumors

FHD-609 is a Selective, Potent, Protein Degrader of the BRD9 component of the BAF complex

FHD-609 TARGETS AND DEGRADES THE BRD9 SUBUNIT OF BAF WHICH IS REQUIRED FOR SYNOVIAL SARCOMA CELLS TO SURVIVE

Selective, Potent BRD9 Targeted Protein Degrader

Target / Approach	• BRD9 • Intravenous protein degrader
Initial Indication	• Synovial sarcoma • SMARCB1-Loss Tumors
Mutation / Aberration	• SS18-SSX1 / SSX2 / SSX4 protein fusions
Program Status / Milestones	• Initial clinical data expected 2023
New Patients Impacted / Year*	• Synovial sarcoma: Over 1,800 • SMARCB1-Loss Tumors: ~ 1,000

BRD9 IS REQUIRED FOR THE SURVIVAL OF SYNOVIAL SARCOMA CELLS



* U.S., EU5, Japan

FHD-609 CLINICAL DEVELOPMENT PLAN

PHASE 1 DOSE ESCALATION STUDY

- Metastatic Synovial Sarcoma and SMARCB1-Loss Tumors

Phase 1 Study Design	• Single patient accelerated titration (n=1) • Convert to 3+3 once relevant PK / PD, safety or clinical activity observed • Assess safety, PK, clinical activity and biomarkers
Biomarkers	• SS18-SSX1, SS18-SSX2 or SS18-SSX4 translocation

PHASE 1 EXPANSION STUDIES

- Metastatic synovial sarcoma expansion cohorts
- SMARCB-1 deleted tumors and potentially other indications

POTENTIAL DEFINITIVE EFFICACY TRIALS & INDICATION EXPANSION

- Potential for entry into definitive efficacy trials in metastatic synovial sarcoma
- Potential for indication expansion beyond metastatic synovial sarcoma

ON-TREATMENT TUMOR BIOPSIES WITH FHD-609 DEMONSTRATE TARGET ENGAGEMENT WITH DEGRADATION OF BRD9



ROBUST *IN VIVO* ACTIVITY OBSERVED IN SYNOVIAL SARCOMA MODEL AND BRD9 DEGRADATION ASSOCIATED WITH FHD-609 TREATMENT

Weekly Dosing of FHD-609 Achieved Sustained BRD9 Degradation

SY01 SYNOVIAL SARCOMA CDX MODEL

- Mutation: **SS18-SSX2**
- Inhibited tumor growth
- Dose-dependent BRD9 degradation correlated with anti-tumor activity



SUSTAINED BRD9 DEGRADATION



SUPERIOR TUMOR GROWTH INHIBITION WITH FHD-609 IN A SYNOVIAL SARCOMA MODEL AS COMPARED TO IFOSFAMIDE AND PAZOPANIB

ASKA CDX MODEL

- Mutation: **SS18-SSX1**
- Superior tumor growth inhibition compared to ifosfamide and pazopanib
- Complete suppression observed over 30 days at 2 mg / kg of FHD-609



FHD-609 IS HIGHLY SELECTIVE

No Off-Target IMiD Neosubstrate Degradation Activity Observed

KINETIC DEGRADATION PROFILING



ENDPOINT DEGRADATION PROFILING



FHD-609 SELECTIVELY DEGRADES BRD9 IN SYNOVIAL SARCOMA GLOBAL PROTEOMICS ANALYSES

BRD9 is the Only Protein Significantly Degraded at Multiple Concentrations and Time Points

16nM (200x DC50) 4hrs in SYO1



78nM (1000x DC50) 4hrs in SYO1



16nM (200x DC50) 24hrs in SYO1



FOGHORN THERAPEUTICS

SELECTIVE BRM MODULATORS

FOR BRG1 MUTATED CANCERS

Enzymatic Inhibitor and Protein Degrader Programs targeting BRG1 mutated cancers (e.g., NSCLC), 30+ cancers with BRG1 mutations

BRG1 MUTATIONS CREATE A GENETIC DEPENDENCY ON BRM

Selective BRM Modulators Overview

Target / Approach	• BRM • Enzymatic inhibitor • Targeted protein degrader
Indications	• BRG1 mutated cancers (e.g., NSCLC), 30+ cancers with BRG1 mutations
Mutation / Aberration	• BRG1
Stage	• Pre-clinical
New Patients Impacted / Year*	• > 100,000
Economics of Lilly Collaboration	• 50/50 U.S. economics • Tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties

* U.S., EU5, Japan





BRG1 MUTATED IN ~5% OF ALL TUMORS

Broad Addressable Patient Population

BRG1 MUTATED ACROSS RANGE OF TUMORS



BRG1 MUTATED IN UP TO 10% OF NSCLC TUMORS, MINIMAL OVERLAP WITH OTHER MUTATIONS



BRM SELECTIVE INHIBITOR *IN VIVO* EFFICACY

Demonstrates PK / PD and *In Vivo* Efficacy in a BRG1 Mutant Lung CDX Model



ENZYMATIC SELECTIVITY APPROACHING 200X ACHIEVED



ADVANCING BRM SELECTIVE DEGRADERS

Achieving Complete BRM Degradation

BRM / BRG1 HIBIT DATA



A549 TEN-DAY PROLIFERATION ASSAY



DEGRADERS CAUSE TIME- AND DOSE-DEPENDENT BRM DEGRADATION, ANTIPROLIFERATIVE EFFECTS IN A549 BRG1 MUTANT NSCLC LUNG MODEL

FOGHORN THERAPEUTICS

SELECTIVE ARID1B PROTEIN DEGRADER

FOR ARID1A MUTATED CANCERS

Protein Degrader targeting ARID1A mutated cancers, the most mutated subunit in the BAF complex (e.g., ovarian, endometrial, colorectal, bladder and other cancers)

ARID1A: MOST MUTATED SUBUNIT IN BAF COMPLEX – CREATES DEPENDENCY ON ARID1B

Selective ARID1B Protein Degrader Overview

Target / Approach	• ARID1B • Targeted protein degrader
Initial Indication	• ARID1A mutated cancers
Mutation / Aberration	• ARID1A mutations (e.g., ovarian, endometrial, colorectal, bladder and other cancers)
Stage	• Pre-clinical
New Patients Impacted / Year*	• > 175,000





* U.S., EU5, Japan

ARID1A MUTATED CANCERS: SIGNIFICANT OPPORTUNITY

ARID1A Mutated Across Range of Tumors



Hodges et al. 2017

TARGETING ARID1A MUTATED CANCERS: ARID1B PROTEIN DEGRADER

Advantaged by Gene Traffic Control Platform and Protein Degrader Capabilities

GENE TRAFFIC CONTROL PLATFORM

- Platform produces BAF complexes and subcomplexes containing either ARID1A or ARID1B at scale
- Enables proprietary screens against ARID1B

PROTEIN DEGRADER CAPABILITIES

- Utilize protein degrader toolbox to create ARID1B hetero-bifunctional degraders

PROGRAM STATUS

- Validated selective chemical binders of ARID1B
- In process of expanding binders into novel selective protein degraders
- Assessing outcomes of ARID1B degradation and impact on BAF complex formation



Highly purified ARID1B / BAF complex



FOGHORN THERAPEUTICS

SELECTIVE CBP PROTEIN DEGRADER

FOR EP300 MUTATED CANCERS

Implicated in subsets of cancers including bladder, colorectal, breast, gastric and lung

ADVANCING HIGHLY SELECTIVE CBP PROTEIN DEGRADER FOR EP300 MUTATED CANCERS

Selective CBP Protein Degrader Overview

Target / Approach	• CREB binding protein (CBP) • Targeted protein degrader
Initial Indication	• EP300 mutated cancers (e.g., subsets of prostate, bladder, colorectal, breast, gastric and lung cancers)
Mutation / Aberration	• EP300 mutated cancers
Stage	• Pre-clinical
New Patients Impacted / Year*	• Over 100,000



* U.S., EU5, Japan.

ADVANCEMENT OF HIGHLY SELECTIVE DEGRADERS FOR CBP

Selective CBP Degradation Translating to Selective CBP-Dependent Cell Killing

SELECTIVE CBP DEGRADATION (Osteosarcoma Cell Line)



CELL PROLIFERATION ASSAYS (Bladder Cell Line)



FOGHORN THERAPEUTICS

TRANSCRIPTION FACTORS

A NOVEL APPROACH

A NEW APPROACH TO DRUGGING TRANSCRIPTION FACTORS

Enabled by Proprietary Ability to Purify and Synthesize Chromatin Regulatory System Components

TFS ARE COMPELLING DRUG TARGETS…

- Highly involved in gene expression
- Implicated in range of cancers and other diseases

…BUT HISTORICALLY DIFFICULT TO TARGET

- Featureless surface: no druggable binding pocket
- Tight interactions with DNA: undruggable affinities

FOGHORN HAS A NEW APPROACH FOCUSING ON INTERACTION WITH BAF

- Druggable binding pockets
- Druggable affinities

FOGHORN'S FOCUS



TRANSCRIPTION FACTOR–CHROMATIN REMODELING COMPLEX INTERACTIONS

Unique Insights in Where and How Transcription Factors Bind

Transcription Factors (TF):



HIGHLY SCALABLE APPROACH TO ADDRESS SIGNIFICANT UNMET MEDICAL NEED DRIVES MERCK COLLABORATION

Potential to Drug > 100 TFs Associated with BAF

TRANSCRIPTION FACTOR DISRUPTORS



- >100 TFs estimated associated with BAF
- Foghorn pursuing multiple TFs in parallel
- Approach highly scalable and potential broad application – other chromatin remodeling complexes and other diseases

MERCK

- Merck collaboration to drug single specified transcription factor target
- $15 million upfront; up to $410 million in research, development, regulatory and sales-based milestones
- Up to low double-digit royalties on product sales

BROAD PIPELINE ACROSS A RANGE OF TARGETS AND MODALITIES

Precision Oncology / Breadth and Depth / Over 15 Programs

* Per year incidence U.S., EU5, Japan

FIRST-IN-CLASS PRECISION MEDICINES TARGETING CANCER AND OTHER DISEASES

LARGE MARKET POTENTIAL

Chromatin biology implicated in up to **50% of cancer**, potentially impacting **~2.5 million patients**

Potential applications in virology, autoimmune diseases and neurology

WELL-FUNDED

$ 373.5 million in cash and equivalents

(as of 9/30/2022)

UPCOMING MILESTONES

FHD-286: Initial clinical data for mUM expected H1'23

FHD-286: AML/MDS study on full clinical hold, initial clinical data TBD

FHD-609: Initial clinical data expected in 2023

SIGNIFICANT GLOBAL PARTNERSHIPS

Strategic collaboration with Loxo Oncology at Lilly; $380 million upfront; 50/50 U.S. economic split on two lead programs

Merck collaboration to drug single specified transcription factor target; $15 million upfront and up to $410 million in milestones

EXPERIENCED LEADERSHIP TEAM

Expertise across drug discovery, clinical development and commercialization

APPENDIX

PLATFORM & DRUGGING CAPABILITIES

PLATFORM IS POWERED BY ABILITY TO PRODUCE COMPONENTS AT SCALE

Drives Drug Discovery Pipeline with Cutting Edge Technology

PRODUCTION OF CHROMATIN REGULATORY SYSTEM COMPONENTS





	FEATURES	BENEFITS
	Surface Mapping	Characterize TF / BAF Binding Sites
	Assembly	Synthesize subcomplexes to enable drug discovery
	Affinity Screening & Validation	ASMS on full complex to yield novel degraders
	HTS	Multiple screening options with full complex
	Biophysics/SPR	Validation of novel small molecule binders

PROTEIN DEGRADER PLATFORM

CURRENT APPROACH

- A leader in developing heterobifunctional degraders for clinical evaluation in oncology
- Employing PROTAC and non-CRBN based molecular glue degradation approaches

DEGRADER CHEMICAL TOOLBOX

- Proprietary library of drug-like linkers, E3 ligase binders and potential glues
- Chemistry to rapidly identify and optimize degraders

ADVANCED MECHANISTIC CHARACTERIZATION

- Native target turnover understanding
- Cellular degradation kinetics and rates
- Structural, biochemical and cellular ternary complex characterization
- Global proteomics and ubiquitination studies
- Computational modeling of degraders
- Degradation efficacy across multiple cell types

OPTIMIZATION OF DEGRADER DRUG PROPERTIES

- Guidelines for both of oral and IV-administered degraders
- PK / PD, efficacy and safety modeling to optimize dosing and scheduling





FOGHORN THERAPEUTICS

STRATEGIC PARTNERSHIP

LOXO ONCOLOGY AT LILLY

STRATEGIC COLLABORATION WITH LOXO ONCOLOGY AT LILLY

Foghorn to Lead Discovery and Research Activities

$380 MILLION UPFRONT

$300 million cash payment

$80 million investment in Foghorn common stock at a price of $20 per share

50/50 U.S. ECONOMICS ON TWO PROGRAMS

50/50 U.S. economic split on BRM-Selective and another undisclosed program

Tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties based on revenue levels

THREE UNDISCLOSED DISCOVERY PROGRAMS

Option to participate in a percentage of the U.S. economics

Tiered ex-U.S. royalties from the mid-single digit to low-double digit range

$1.3 billion in potential milestones

FOGHORN THERAPEUTICS

THE CHROMATIN REGULATORY SYSTEM

Orchestrates Gene Expression

THE CHROMATIN REGULATORY SYSTEM ORCHESTRATES GENE EXPRESSION

Two Major Components Work in Concert: Chromatin Remodeling Complexes and Transcription Factors



CHROMATIN

Chromatin – compacted form of DNA inside the nucleus of the cell

1 | CHROMATIN REMODELING COMPLEX AND TRANSCRIPTION FACTOR

Work together to orchestrate gene expression





2 | RIGHT GENES

TFs guide chromatin remodeling complexes to the right locations

3 | NORMAL GENE EXPRESSION

Once chromatin unpacked, gene expression can occur



BREAKDOWNS IN THE CHROMATIN REGULATORY SYSTEM CAN LEAD TO DISEASE



Mutations or overexpression in chromatin remodeling complexes result in abnormal gene expression

Abnormal Gene Expression

DISEASE

Mutated or overexpressed TF hijacks chromatin remodeling complex to wrong location



Abnormal Gene Expression

DISEASE

CHROMATIN REGULATORY SYSTEM

Abundance of Targets within the BAF Complex



28 Chromatin Remodeling Complexes and >1,000 TFs

BAF Complex Subunits Mutated and Dysregulated in Cancer

Estimate >100 Transcription Factors Associated with Just the BAF Complex

Leadership Team, Board & Advisors

Expertise across drug discovery, clinical development and commercialization

PROVEN LEADERSHIP TEAM

ADRIAN GOTTSCHALK
President & CEO

SAM AGRESTA, M.D., M.P.H & TM
Chief Medical Officer

MICHAEL LACASCIA
Chief Legal Officer

ALLAN REINE, M.D.
Chief Financial Officer

STEVE BELLON, PH.D.
Chief Scientific Officer

FANNY CAVALIE
Chief Strategy and Business Operations Officer

CARLOS COSTA
Chief People Officer

SAURABH SEWAK
VP, Corporate Development

BEN STRAIN
VP, Investor Relations & Corporate Communications

CHONG-HUI GU, PH.D.
VP, CMC and QA

NICOLA MAJCHRZAK
VP, Clinical Development Operations

DANETTE L. DANIELS, PH.D.
VP, Protein Degrader Platform

KARIN HELLSVIK
VP, Corporate Affairs

ANDREW GERMAIN
VP, Legal

SCOTT INNIS
VP, Program Leadership

JACQUELINE CINICOLA
VP, Regulatory Affairs

MURPHY HENTEMANN
VP, Program Leadership

KEVIN WILSON
VP, Chemistry

MARINA NELEN
VP, Drug Discovery

INDUSTRY-LEADING BOARD OF DIRECTORS AND ADVISORS

BOARD OF DIRECTORS

DOUG COLE, M.D.
Flagship Pioneering – Board Chair; Founder

SCOTT BILLER, PH.D.
Former CSO and Strategic Advisor, Agios

SIMBA GILL, PH.D.
Evelo Biosciences, Partner at Flagship Pioneering

ADRIAN GOTTSCHALK
Foghorn President & CEO

THOMAS J. LYNCH, JR., M.D.
Fred Hutchinson Cancer Center

B. LYNNE PARSHALL, ESQ.
Senior Strategic Advisor, Ionis Pharmaceuticals

ADAM KOPPEL, M.D., PH.D.
Bain Capital Life Sciences

MICHAEL MENDELSOHN, M.D.
Cardurion Pharmaceuticals

IAN SMITH
Exec. Chair of Solid Bio., Chair of ViaCyte, Former COO of Vertex

SCIENTIFIC & OTHER ADVISORS

CHARLES SAWYERS, M.D.
MSKCC, HHMI – SAB Chair

CRAIG PETERSON, PH.D.
Professor, UMass Medical School

GERALD CRABTREE, M.D.
Stanford, HHMI; Founder

DAVID SCHENKEIN, M.D.
General Partner, GV

TONY KOUZARIDES, PH.D.
Gurdon Institute – University of Cambridge

CIGALL KADOCH, PH.D.
Dana-Farber, Broad, HMS, HHMI; Founder